ALPHA: ALitretinoin versus PUVA in severe chronic HAnd eczema trial

View pages in this document

Alpha logoThe ALPHA trial compares Alitretinoin and PUVA therapy in patients aged 18 years and over with severe hand eczema which is not controlled on a daily (regular) basis with prescription steroid creams.



December 2016: 

  1. Best ever month for recruitment to the ALPHA study- 19 patients registered! More than 150 participants registered and 97 participants randomised onto the study so far - what a great way to end the year! Well done to all the teams for all your hard work.

  2. Welcome to New Cross Hospital and Cannock Chase Hospital, both within Royal Wolverhampton NHS Trust. Good luck with your recruitment for the ALPHA study.

November: 2016 

  1. Welcome to University Hospitals Bristol NHS Foundation Trust, our latest centre open to recruitment to the ALPHA Study!

  2. There are now 120 registered participants for ALPHA- well done everyone and thank you to all our participants.

BBC Look North (Yorkshire) features Dr Miriam Wittmann discussing the ALPHA trial - click the link ( to watch the full programme. Here's a shortened version of the video on the BBC Look North face book page:


For earlier news feed items please go here

Want to know more?

Alpha patient zone 4Alpha hospitalsAlpha potential investigators

If you can't find a hospital near you, please keep checking regularly as more hospitals will be added as they are opened to recruitment.

Contact us

Are you a hospital based clinician who would like to take part in the ALPHA trial?  

Are you a research active GP practice? Would you like to refer patients with severe chronic hand eczema to a local ALPHA participating hospital?

If so, please contact Victoria Goss, Senior Trial Coordinator for more details:

Victoria Goss
Senior Trial Coordinator
Tel: 0113 343 4317


Hand eczema, hand dermatitis, clinical trial, ALPHA, research, Alitretinoin, PUVA, GP, NHS, NIHR HTA

 Hands up web size


Pages in this document

  1. ALPHA: ALitretinoin versus PUVA in severe chronic HAnd eczema trial
  2. Earlier news from the ALPHA trial